Physician profile
John Thomas Cottingham
NPI 1194866996
$1,774.99
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $404 · 2020: $229 · 2021: $446 · 2022: $478 · 2023: $133 · 2024: $85.73.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $218.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $218.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $370.13 | 2019-2022 | |
| Astellas Pharma US INC | $266.17 | 2019-2024 | Veozah, Myrbetriq |
| Amarin Pharma, INC. | $230.24 | 2019-2022 | |
| Glaxosmithkline, LLC. | $213.99 | 2020-2023 | Trelegy Ellipta |
| Esperion Therapeutics, INC. | $120.17 | 2021 | |
| Novo Nordisk INC | $111.17 | 2019-2022 | |
| Abbott Laboratories | $107.47 | 2022-2024 | Freestyle Libre 3, Proclaim |
| Abbvie INC. | $96.00 | 2021-2024 | |
| Amgen INC. | $66.29 | 2019-2022 | |
| Pfizer INC. | $47.64 | 2019 | |
| Merck Sharp & Dohme LLC | $27.42 | 2022 | |
| Idorsia Pharmaceuticals US INC | $18.56 | 2022 | |
| Arbor Pharmaceuticals, INC. | $15.80 | 2019 | |
| Allergan, INC. | $15.54 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.46 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $15.18 | 2019 | |
| Janssen Pharmaceuticals, INC | $14.39 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.31 | 2019 | |
| Genentech USA, INC. | $11.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Cottingham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.